ZAFGEN, INC.
LRMR US5171251003
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Hamilton Thomas Edward |
8.74 USD |
57,208 Bought |
499,998 USD |
16/02/2024 | 16/02/2024 |
Thomas Frank E |
11.00 USD |
2,000 Bought |
22,000 USD |
14/02/2024 | 14/02/2024 |
Shankar Gopi BDM |
3.73 USD |
5,000 Bought |
18,662 USD |
07/12/2023 | 07/12/2023 |